TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31364889
Drug: E2/P4 (1 mg/100 mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2/P4 (1 mg/100 mg, 0.5 mg/100 mg, 0.5 mg/50 mg, 0.25 mg/50 mg)
Study: 12923404
Drug: 0.3 mg/day
Normalized name: cloNIDine HCl 0.3 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/day moxonidine
Study: 12923404
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day nitrendipine
Study: 9988808
Drug: Sulindac (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac (200 mg orally every 12 hours for 6 doses)
Study: 9988808
Drug: Terbutaline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (5 mg orally every 4 hours for 72 hours)
Study: 2148827
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (IB) (0.5 mg)
Study: 2148827
Drug: Home nebulizer
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home nebulizer treatment (salbutamol, ipratropium bromide, mixture)
Study: 7437277
Drug: Dipyrone 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone 1.0 g (tooth extraction)
Study: 7437277
Drug: Paracetamol 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1.0 g (tooth extraction)
Study: 31902311
Drug: New Zealand
Normalized name: NEW ZEALAND GREEN MUSSEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: New Zealand blackcurrant extract (600 mg·day-1 CurraNZ™)
Study: 31902311
Drug: Placebo (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (600 mg microcrystalline cellulose)
Study: 29788230
Drug: Trastuzumab/Pertuzumab-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab/Pertuzumab-based chemotherapy
Study: 29692179
Drug: Intravenous belimumab
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous belimumab plus standard therapy
Study: 29692179
Drug: Subcutaneous belimumab
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous belimumab plus standard therapy
Study: 12082358
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (gonadotropin-releasing hormone) administered via four monthly injections and estradiol patch during testing
Study: 7872446
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% clotrimazole
Study: 7872446
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% miconazole
Study: 29447733
Drug: Stroke risk
Normalized name: Hep B, adolescent/high risk infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stroke risk model based on older age, Killip class 3 or 4, estimated glomerular filtration rate ≤45 ml/min/1.73 m2, hypertension history, and previous stroke.
Study: 18595128
Drug: 72 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 72 weeks of pegylated interferon and ribavirin treatment for genotype 1-infected slow responders
Study: 18595128
Drug: 48 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 48 weeks of pegylated interferon and ribavirin treatment for genotype 1-infected slow responders
Study: 12562461
Drug: Oral desensitization
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral desensitization treatment
Study: 10836202
Drug: Estrogen replacement
Normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen replacement therapy (ERT) with 50 micrograms/day of 17 beta‐estradiol
Study: 9098205
Drug: Adenosine triphosphate
Normalized name: Adenosine triphosphate
DrugBank: ATP (DB00171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine triphosphate (ATP) at a dose of 0.16 mg/kg/min
Study: 9098205
Drug: Dipyridamole (DIP)
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dipyridamole (DIP) at a dose of 0.56 mg/kg
Study: 8473679
Drug: BAY u
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY u 3405 (20 mg, single oral dose)
Study: 28541645
Drug: Raloxifene 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 120 mg/d plus antipsychotics
Study: 28541645
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus antipsychotics
Study: 23557025
Drug: Doxycycline 20
Normalized name: doxycycline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 20 mg b.i.d. for 3 months
Study: 20946157
Drug: Idrabiotaparinux (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idrabiotaparinux (3 mg)
Study: 23078631
Drug: Idraparinux (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idraparinux (2.5 mg)
Study: 12539808
Drug: Simvastatin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (all doses)
Study: 10766085
Drug: Postoperative irradiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative irradiation combined with chemotherapy
Study: 8793166
Drug: Moexipril 3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moexipril 3.75 mg
Study: 8793166
Drug: Moexipril 7.5
Normalized name: moexipril 7.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moexipril 7.5 mg
Study: 8793166
Drug: Moexipril 15
Normalized name: moexipril 15 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moexipril 15 mg
Study: 6699319
Drug: Jet nebulizer
Normalized name: Pari LC Jet Nebulizer Plus RE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jet nebulizer therapy with metaproterenol sulfate solution 15 mg in 2.3 ml
Study: 6699319
Drug: Canister therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canister therapy with metered-dose metaproterenol sulfate (total 1.95 mg)
Study: 6699319
Drug: Jet nebulizer
Normalized name: Pari LC Jet Nebulizer Plus RE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jet nebulizer therapy and Canister therapy
Study: 26861468
Drug: Structured pharmacist
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured pharmacist review of medication (SPRM) with computerised clinical decision support software (CDSS)
Study: 24371832
Drug: Water extracts
Normalized name: water birch pollen extract
DrugBank: Betula occidentalis pollen (DB10832)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water extracts of Graptopetalum paraguayense (WGP, 4 g/d)
Study: 15499981
Drug: 1% ephedrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% ephedrine nosedrop, antibiotic, antihistamine, and anisodamine (10 mg twice a day)
Study: 15499981
Drug: 1% ephedrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% ephedrine nosedrop, antibiotic, and antihistamine
Study: 7710217
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 2 mg plus IM Ketorolac 30 mg (Group B)
Study: 7710217
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 2 mg plus IM placebo (Group A)
Study: 7710217
Drug: Epidural saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural saline placebo plus IM Ketorolac 30 mg (Group C)
Study: 30195447
Drug: Mesalazine 3
Normalized name: mesalazine 375 MG 24 HR Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine 3 g once daily
Study: 23188412
Drug: recombinant LH
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant LH (r-LH) administration during late follicular development stages
Study: 23188412
Drug: recombinant LH
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant LH (r-LH) administration
Study: 20651460
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg Fe as ferric pyrophosphate
Study: 20651460
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg Fe as ferric pyrophosphate and 1.25 g DFAIII
Study: 20651460
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg Fe as ferrous sulfate
Study: 19213340
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment + small dose prednisone
Study: 19213340
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment + Chinese herbal medicine
Study: 19213340
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment only (Control Group A)
Study: 15798461
Drug: Glutamine-supplemented parenteral
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine-supplemented parenteral nutrition (GlnPN; glutamine target intake, 0.4 g kg day; n = 41)
Study: 15798461
Drug: Standard parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard parenteral nutrition (sPN; n = 39)
Study: 12662915
Drug: Ethyl oleate
Normalized name: Ethyl Oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethyl oleate (EO) at 8 g/day in a single serving (approximately 0.1 g/kg)
Study: 12662915
Drug: Ethyl oleate
Normalized name: Ethyl Oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethyl oleate (EO) at 16 g/day taken in two divided servings (approximately 0.2 g/kg)
Study: 30672238
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with acupuncture combined with rehabilitation training
Study: 26712382
Drug: Body weight‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body weight‐based prednisolone dosing
Study: 26712382
Drug: Body surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body surface area‐based prednisolone dosing
Study: 23434957
Drug: Caudal analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal analgesia with 0.75 ml/kg of 0.25% bupivacaine with 1 μg/kg of clonidine in normal saline (Group BC)
Study: 23434957
Drug: Caudal analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal analgesia with 0.75 ml/kg of 0.25% bupivacaine with ketamine 0.5 mg/kg (Group BK)
Study: 23434957
Drug: Caudal analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal analgesia with 0.75 ml/kg of 0.25% bupivacaine with fentanyl 1 mcg/kg (Group BF)
Study: 23434957
Drug: Caudal analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal analgesia with 0.75 ml/kg of 0.25% bupivacaine in normal saline (Group B)
Study: 20378497
Drug: L-LV (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-LV (100 mg/m2)
Study: 20378497
Drug: DL-LV (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: DL-LV (200 mg/m2)
Study: 15843938
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of oral antibiotics (neomycin and metronidazole) at the time of mechanical colon cleansing
Study: 15843938
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of oral antibiotics
Study: 29684391
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral antibiotics
Study: 10605328
Drug: Nifidipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifidipine GITS 30 and 60 mg
Study: 9166464
Drug: Adjuvant CMF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant CMF (cyclophosphamide, methotrexate, fluorouracil) chemotherapy for 6 months
Study: 1932652
Drug: Cardioplegic solution
Normalized name: cardioplegic solution no.2
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cardioplegic solution enriched with creatine phosphate (10 mmol/L)
Study: 31658994
Drug: Ipilimumab with
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab with concurrent stereotactic radiation therapy (50 Gy in 4 fractions)
Study: 31658994
Drug: Ipilimumab with
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab with sequential stereotactic radiation therapy (60 Gy in 10 fractions)
Study: 31658994
Drug: Sequential lung
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential lung group
Study: 26934128
Drug: Premixed insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premixed insulin lispro protamine suspension 75%/insulin lispro solution 25% (LM25) twice daily (bid)
Study: 26934128
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin glargine plus prandial insulin lispro (IGL), once daily
Study: 23046566
Drug: JUC (nanotechnology
Approvals — FDA: no, EMA: no, PMDA: no
Description: JUC (nanotechnology antimicrobial spray)
Study: 15947981
Drug: Theophylline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (5 mg/kg; study group: n=20)
Study: 11812509
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (0.2, 0.4, and 0.8 mg)
Study: 11812509
Drug: D-amphetamine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-amphetamine (15 mg, oral)
Study: 9916865
Drug: Insulin-tolerance test
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-tolerance test (ITT)
Study: 2647495
Drug: gallopamil 75
Normalized name: gallopamil
DrugBank: Gallopamil (DB12923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gallopamil 75 mg t.i.d.
Study: 29174683
Drug: HZ/su administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: HZ/su administered 0, 6-month schedule
Study: 29174683
Drug: HZ/su administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: HZ/su administered 0, 12-month schedule
Study: 29174683
Drug: All dosing
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All dosing intervals
Study: 26294706
Drug: Integrated mental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated mental health and substance abuse treatments for at least the first 3 years
Study: 1352428
Drug: Apraclonidine 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apraclonidine 1% instilled one hour before and immediately after laser treatment
Study: 6725520
Drug: 1.5 micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 micrograms/kg oral clonidine
Study: 6725520
Drug: 5.0 micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 micrograms/kg oral clonidine
Study: 30103220
Drug: Single-dose Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-dose Azithromycin
Study: 27344826
Drug: Fluoxetine hydrochloride
Normalized name: Fluoxetine Hydrochloride
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine hydrochloride capsules (oral administration, once a day for 4 weeks)
Study: 25012999
Drug: Task-specific training
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Task-specific training conducted by physical therapists in participants' homes, focusing on walking, sit-to-stand transfers, and standing, twice a week for 8 weeks.
Study: 20484057
Drug: DHEA 50
Normalized name: Natrol Mood & Stress DHEA 50mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 50 mg/day for 6 months
Study: 18584574
Drug: Levetiracetam (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (2000 mg daily for 10 weeks)
Study: 15975721
Drug: Veno-venous continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veno-venous continuous renal replacement therapy (CRRT)
Study: 12468480
Drug: Informing participants
Normalized name: INFORMATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Informing participants of their treatment allocation at trial closure
Study: 12468480
Drug: Not informing
Normalized name: INFORMATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not informing participants of their treatment allocation at trial closure
Study: 9799054
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg pantoprazole p.o. once daily for 11 days
Study: 7617798
Drug: Oral ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ethanol (1.1 ml/kg 95% ethanol as a 20% solution)
Study: 7617798
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of ethanol and yohimbine
Study: 325238
Drug: Propoxyphene napsylate
Normalized name: Propoxyphene Napsylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propoxyphene napsylate (50 or 100 mg)
Study: 325238
Drug: Codeine sulfate
Normalized name: Codeine Sulfate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine sulfate (30 or 60 mg)
Study: 28374923
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) supplementation, 2 g/day for 9 weeks
Study: 23617452
Drug: Empagliflozin 200
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin 200 mg
Study: 21718491
Drug: Ischemic preconditioning
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ischemic preconditioning (IPC) administered 4 hours prior to ischemia
Study: 21718491
Drug: Ischemic preconditioning
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ischemic preconditioning (IPC) administered 48 hours prior to ischemia
Study: 11114494
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg buspirone
Study: 17329302
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg buspirone
Study: 11236537
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy (six series of polychemotherapy with cisplatin 50 mg/m2, adriamycin 50 mg/m2, and cyclophosphamide 500 mg/m2)
Study: 8286880
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (39 mg/day)
Study: 2424279
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin (5,000 IU X 2 s.c.) started preoperatively and continued daily for one week post-operatively
Study: 2424279
Drug: Per-operative electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Per-operative electrical calf muscle stimulation with groups of impulses plus post-operative dextran infusions every other day for one week
Study: 30784726
Drug: Sham LFMS
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham LFMS treatment
Study: 23907736
Drug: Biofeedback therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback therapy during dental restorations
Study: 20130470
Drug: Mifepristone 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 75 mg
Study: 20130470
Drug: Mifepristone 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 150 mg
Study: 20130470
Drug: Mifepristone 225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 225 mg
Study: 17335685
Drug: Thalidomide as
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide as maintenance therapy after double ASCT
Study: 17335685
Drug: Combinations of
Normalized name: Combinations of vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combinations of conventional chemotherapy with novel agents (thalidomide or bortezomib)
Study: 10825326
Drug: Ephedrine 30
Normalized name: ephedrine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 30 mg IV
Study: 10825326
Drug: Ephedrine 10
Normalized name: pseudoephedrine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 10 mg IV
Study: 10825326
Drug: Ephedrine 20
Normalized name: DM 10/PSEUDOEPHEDRINE 20MG/5ML LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 20 mg IV
Study: 1430132
Drug: RU 486
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486 treatment for 12 hours
Study: 1430132
Drug: RU 486
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486 treatment for 24 hours
Study: 6494068
Drug: Topical steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroids (six different potencies), applied once daily without occlusion
Study: 6494068
Drug: Topical steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroids (six different potencies)
Study: 2883906
Drug: Metoprolol 25
Normalized name: metoprolol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 25 mg
Study: 2883906
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no beta-adrenoreceptor antagonist)
Study: 23311602
Drug: MEAW technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEAW technique with modified Class III elastics from maxillary mini-implants
Study: 21638181
Drug: Diaphragmatic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diaphragmatic injection of bupivacaine
Study: 21638181
Drug: Topical wash
Normalized name: BP 5% Topical Wash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical wash with bupivacaine
Study: 21638181
Drug: Control (sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (sham injection and sham wash)
Study: 11193132
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate aerosol (1.25 mg)
Study: 11193132
Drug: Sublingual isosorbide
Normalized name: isosorbide dinitrate Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual isosorbide dinitrate tablet (5 mg)
Study: 9196354
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (half the dose)
Study: 9196354
Drug: Budesonide (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (high doses)